Cipla, India's second largest pharmaceutical company, posted impressive performance during the year ended March 2006 and its net profit went up by 46.5 per cent to Rs 600 crore from Rs 410 crore in the previous year. The company's net sales also improved by 36.8 per cent to Rs 2986 crore from Rs 2181 crore. The earning per share worked out to Rs 20.01 for the FY 2006.

The company raised Rs 762.20 crore through an issue of GDR during April 2006. The said GDRs have been listed on the Luxembourg Stock Exchange and the company has already applied to BSE and NSE for having the underlying shares listed. The board of directors recommended the issue of bonus shares in the ratio of three shares for every two share held and the shareholders have approved the same through a postal ballot. The record date was fixed as April 25.

Consequent to the issue of GDR and bonus shares the paid-up equity share capital will stand increased to Rs 155.46 crore from present Rs 59.97 crore. To accommodate these new shares, the company has increased its authorized equity capital to Rs 175 crore from Rs 65 crore.

The company received total insurance claim of Rs 92.42 crore and the claim received has been accounted as other income. The other income for the year 2005-06 amounted to Rs 131.1 crore as against Rs 155.24 crore in the previous year.